138 related articles for article (PubMed ID: 30684558)
21. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
Rosenberg SA; Yang JC; Robbins PF; Wunderlich JR; Hwu P; Sherry RM; Schwartzentruber DJ; Topalian SL; Restifo NP; Filie A; Chang R; Dudley ME
J Immunother; 2003; 26(5):385-93. PubMed ID: 12973027
[TBL] [Abstract][Full Text] [Related]
22. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
23. Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.
Maeurer MJ; Hurd S; Martin DM; Storkus WJ; Lotze MT
Cancer J Sci Am; 1995; 1(2):162-70. PubMed ID: 9166469
[TBL] [Abstract][Full Text] [Related]
24. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
25. Genetic evolution of T-cell resistance in the course of melanoma progression.
Sucker A; Zhao F; Real B; Heeke C; Bielefeld N; Maβen S; Horn S; Moll I; Maltaner R; Horn PA; Schilling B; Sabbatino F; Lennerz V; Kloor M; Ferrone S; Schadendorf D; Falk CS; Griewank K; Paschen A
Clin Cancer Res; 2014 Dec; 20(24):6593-604. PubMed ID: 25294904
[TBL] [Abstract][Full Text] [Related]
26. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
27. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.
Del Campo AB; Carretero J; Muñoz JA; Zinchenko S; Ruiz-Cabello F; González-Aseguinolaza G; Garrido F; Aptsiauri N
Cancer Gene Ther; 2014 Aug; 21(8):317-32. PubMed ID: 24971583
[TBL] [Abstract][Full Text] [Related]
29. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
Chapon M; Randriamampita C; Maubec E; Badoual C; Fouquet S; Wang SF; Marinho E; Farhi D; Garcette M; Jacobelli S; Rouquette A; Carlotti A; Girod A; Prévost-Blondel A; Trautmann A; Avril MF; Bercovici N
J Invest Dermatol; 2011 Jun; 131(6):1300-7. PubMed ID: 21346771
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
31. Lymphocyte-melanoma interaction: role of surface molecules.
Becker JC; Bröcker EB
Recent Results Cancer Res; 1995; 139():205-14. PubMed ID: 7597291
[TBL] [Abstract][Full Text] [Related]
32. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
33. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
34. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression.
Wang Z; Margulies L; Hicklin DJ; Ferrone S
Tissue Antigens; 1996 May; 47(5):382-90. PubMed ID: 8795138
[TBL] [Abstract][Full Text] [Related]
35. [Cytotoxic T-cell immune response against melanoma antigens].
Ayyoub M
Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
[No Abstract] [Full Text] [Related]
36. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors.
Tao J; Li Y; Liu YQ; Li L; Liu J; Shen X; Shen GX; Tu YT
Br J Dermatol; 2008 Jan; 158(1):88-94. PubMed ID: 17999701
[TBL] [Abstract][Full Text] [Related]
37. HLA-G expression in malignant melanoma.
Rebmann V; Wagner S; Grosse-Wilde H
Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5.
Tsukahara T; Kawaguchi S; Torigoe T; Asanuma H; Nakazawa E; Shimozawa K; Nabeta Y; Kimura S; Kaya M; Nagoya S; Wada T; Yamashita T; Sato N
Cancer Sci; 2006 Dec; 97(12):1374-80. PubMed ID: 16995877
[TBL] [Abstract][Full Text] [Related]
39. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
40. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
Wang X; Schoenhals JE; Li A; Valdecanas DR; Ye H; Zang F; Tang C; Tang M; Liu CG; Liu X; Krishnan S; Allison JP; Sharma P; Hwu P; Komaki R; Overwijk WW; Gomez DR; Chang JY; Hahn SM; Cortez MA; Welsh JW
Cancer Res; 2017 Feb; 77(4):839-850. PubMed ID: 27821490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
